Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden and SEB in connection with Clavister investment
Mandate

Vinge advises Industrifonden and SEB in connection with Clavister investment

April 16, 2012

Vinge has advised Industrifonden and SEB Venture Capital in connection with their approximately SEK 40 million investment in the security company Clavister AB. The company, which has its registered office in Örnsköldsvik, offers advanced security products focusing on the telecoms industry, cloud computing environments and large corporate customers. The capital will be used for the company’s future international expansion.

SEB Venture Capital was founded in 1995 and is part of the SEB group. With a capital base of SEK 2 500 million, the company has thus far made 36 investments in technology and healthcare enterprises and performed 36 exits. Read more about SEB Venture Capital by visiting www.seb.se/venturecapital

Industrifonden has assets worth SEK 3.8 billion and investments in 89 companies within the technology, cleantech, life science and industrial sectors. This is Industrfonden’s seventh new investment for the financial year comprising 1 July 2011 to 30 June 2012. Read more about Industrifonden by visiting www.industrifonden.se

Vinge’e team consisted of partner Johan Larsson together with associates Philip Watson and Martin Hall.     

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025